

Clinical Perspectives in Rheumatoid Arthritis: Quality of Life, Comorbidities, and Evolving Targets

Resource	Address
Al-Salama Z, et al. Baricitinib: A review in rheumatoid arthritis. <i>Drugs</i> . 2018;78(7):761-772.	https://pubmed.ncbi.nlm.nih.gov/29687421/
Bansback N, et al. The economics of treatment in early rheumatoid arthritis. <i>Best Pract Res Clin Rheumatol</i> . 2009;23:83-92.	https://pubmed.ncbi.nlm.nih.gov/19233048/
Dhillon S. Tofacitinib: A review in rheumatoid arthritis. <i>Drugs</i> . 2017;77(18):1987-2001.	https://pubmed.ncbi.nlm.nih.gov/29139090/
Dowty M, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. <i>Pharmacol Res Perspect</i> . 2019;7(6):e00537.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857076/
Fragoulis G, et al. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. <i>Rheumatology (Oxford)</i> . 2019;58(Suppl 1):i43-54.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390879/
Jegatheeswaran J, et al. Comparison of janus kinase inhibitors in the treatment of rheumatoid arthritis: A systemic literature review. <i>Immunotherapy</i> . 2019;11(8):737-754.	https://pubmed.ncbi.nlm.nih.gov/30955397/
Kohler BM, et al. Current therapeutic options in the treatment of rheumatoid arthritis. <i>J Clin Med</i> . 2019 Jun 28;8(7):938.	https://pubmed.ncbi.nlm.nih.gov/31261785/
Kronzer V, et al. Comorbidities as risk factors for rheumatoid arthritis and their accrual after diagnosis. 2019;94(12):2488-2498.	https://pubmed.ncbi.nlm.nih.gov/31759675/
Ramos AL, et al. Comorbidities in patients with rheumatoid arthritis and their association with patient-reported outcomes: Results of claims data linked to questionnaire survey. <i>J Rheumatol</i> . 2019;46(6):564-571.	https://pubmed.ncbi.nlm.nih.gov/30647170/
Smolen J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying	https://pubmed.ncbi.nlm.nih.gov/28264816/

antirheumatic drugs: 2016 update. <i>Ann Rheum Dis.</i> 2017;76(6):960-977.	
Smolen J, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomized, placebo-controlled, double-blind phase 3 study. <i>Lancet.</i> 2019;393(10188):2303-2311.	https://pubmed.ncbi.nlm.nih.gov/31130260/
Silvagni E, et al. One year in review 2020: Novelties in the treatment of rheumatoid arthritis. <i>Clin Exp Rheumatol.</i> 2020;38(2):181-194.	https://pubmed.ncbi.nlm.nih.gov/32213264/
Taylor P. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. <i>Rheumatology (Oxford).</i> 2019;58(Suppl 1):i17-i26.	https://pubmed.ncbi.nlm.nih.gov/30806707/
Westhovens R, et al. Rheumatoid arthritis: Defining remission in patients with RA in clinical practice. <i>Nature Reviews Rheumatology.</i> 2012;8:445-447.	https://pubmed.ncbi.nlm.nih.gov/22751567/
Xie W, et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: Systematic review and meta-analysis of randomised controlled trials. <i>Ann Rheum Dis.</i> 2019;78(8):1048-1054.	https://pubmed.ncbi.nlm.nih.gov/31088790/

Resources and Societies

Resource	Address
American College of Rheumatology	https://www.rheumatology.org/
Arthritis Foundation	https://www.arthritis.org/
National Rheumatoid Arthritis Society	https://www.nras.org.uk/
Rheumatology Research Foundation	https://www.rheumresearch.org/
World Health Organization	http://www.who.int/chp/topics/rheumatic/en/